HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CF PHARMTECH

20.240

-0.140-0.69%

Volume:45.50K

Turnover:924.08K

Market Cap:8.32B

PE:2.65K

High:20.660

Open:20.360

Low:20.040

Close:20.380

52wk High:48.800

52wk Low:18.100

Shares:411.00M

HK Float Shares:302.00M

Volume Ratio:0.13

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(LYR):0.008

ROE:0.21%

ROA:-0.83%

PB:4.89

PE(LYR):2,648.52

PS:16.61

Loading ...

Overview Company News Filings

CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF001 Inhalation Powder

THOMSON REUTERS

Global Reformulation Breakthrough! CF PHARMTECH's Pulmonary Hypertension Drug IND Accepted

Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion

CF PHARMTECH (02652) Receives CTA Approval for Combined Nasal Spray Targeting Allergic Rhinitis

Bulletin Express

CF PHARMTECH (02652) Receives NMPA Approval for Clinical Trial Application of Olopatadine Mometasone Nasal Spray

CF Pharmtech Inc - Approval of Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray by Nmpa

THOMSON REUTERS

CF PharmTech wins NMPA clinical trial approval for olopatadine-mometasone nasal spray

CF PHARMTECH (02652) Included in Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect

Bulletin Express

CF PharmTech (02652) Announces Monthly Return for February 2026

Bulletin Express

CF PharmTech (02652) Announces Share Repurchase and Updated Shareholdings

Bulletin Express

CF PHARMTECH (02652) Repurchases 30,500 Shares for HK$1.18 Million on February 27

CF PharmTech Files HKEX Next-Day Disclosure Return Reporting 30,500-Share Buyback at HK$38.6905 Each

CF PharmTech (02652) Announces Share Repurchase and Updates Treasury Shares

Bulletin Express

CF PharmTech (02652) Reports Share Repurchase and Updated Issued Shares

Bulletin Express

CF PHARMTECH (02652) Allocates HK$1.2323 Million for Share Buyback on February 25

CF PharmTech files HKEX next-day disclosure return reporting 33,000-share repurchase at HK$37.3409 each

CF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted

CF PharmTech Wins NMPA IND Acceptance for ICF004

CF Pharmtech (HKEX: 2652.HK) Announces Nmpa Acceptance of Ind Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in Pf-Ild

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02652/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"CF PHARMTECH","latestPrice":20.24,"timestamp":1780459500006,"preClose":20.38,"halted":0,"volume":45500,"delay":0,"changeRate":-0.006869479882237516,"floatShares":302000000,"shares":411000000,"eps":0.007642012710702224,"marketStatus":"Noon Closed","change":-0.14,"latestTime":"06-03 12:05:00","open":20.36,"high":20.66,"low":20.04,"amount":924080,"amplitude":0.030422,"askPrice":20.24,"askSize":3000,"bidPrice":20.08,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.007642012710702224,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780462800000},"marketStatusCode":3,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":20.38,"openAndCloseTimeList":[[1780450200000,1780459200000],[1780462800000,1780473600000]],"volumeRatio":0.127386,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":302000000,"roa":"-0.83%","roe":"0.21%","lyrEps":0.007642,"volumeRatio":0.127386,"shares":411000000,"dividePrice":0,"high":20.66,"amplitude":0.030422,"preClose":20.38,"low":20.04,"week52Low":18.1,"pbRate":"4.89","psRate":"16.61","week52High":48.8,"institutionHeld":0,"latestPrice":20.24,"committee":-0.5,"eps":0.007642012710702224,"divideRate":0,"volume":45500,"delay":0,"ttmEps":0.007642012710702224,"open":20.36,"prevYearClose":35,"prevWeekClose":22.22,"prevMonthClose":22.22,"prevQuarterClose":22.16,"fiveDayClose":19.66,"twentyDayClose":22.02,"sixtyDayClose":37.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-06-01","current":2665.19987,"percent":0.839744,"low":-293.764894,"twenty":400.575047,"median":467.575731,"eighty":2963.886694,"high":3595.964728,"avg":1098.551773,"sd":1175.771413,"marketCap":8746652155},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-27","current":505.751529,"twenty":411.273773,"median":459.838493,"eighty":479.42962,"marketCap":16048983093},{"date":"2026-03-06","current":445.246344,"twenty":411.572519,"median":460.887466,"eighty":481.94993,"marketCap":14015073071},{"date":"2026-03-13","current":299.287031,"twenty":402.338985,"median":457.528006,"eighty":481.000215,"marketCap":9464083401},{"date":"2026-03-20","current":315.053976,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"marketCap":9924943114},{"date":"2026-03-27","current":299.095644,"twenty":391.175665,"median":451.779671,"eighty":479.42962,"marketCap":9398246299},{"date":"2026-04-02","current":3318.248683,"twenty":389.832113,"median":451.779671,"eighty":480.872541,"marketCap":9381570423},{"date":"2026-04-10","current":3321.445916,"twenty":390.816678,"median":452.984556,"eighty":482.236241,"marketCap":9463036901},{"date":"2026-04-17","current":3317.060015,"twenty":392.419904,"median":455.282385,"eighty":483.410603,"marketCap":9454509433},{"date":"2026-04-24","current":2996.4431,"twenty":394.891161,"median":460.26919,"eighty":490.336167,"marketCap":8541149514},{"date":"2026-04-30","current":3202.871531,"twenty":396.041553,"median":462.144769,"eighty":499.979081,"marketCap":9131900891},{"date":"2026-05-08","current":3148.404437,"twenty":397.173254,"median":463.774025,"eighty":508.169798,"marketCap":9007763175},{"date":"2026-05-15","current":2973.181714,"twenty":398.099028,"median":464.50673,"eighty":512.854422,"marketCap":8528814526},{"date":"2026-05-22","current":2811.882705,"twenty":399.495195,"median":466.720409,"eighty":2921.871357,"marketCap":8047680823},{"date":"2026-05-29","current":3180.044455,"twenty":400.476536,"median":467.247998,"eighty":2926.706614,"marketCap":9133017429},{"date":"2026-06-01","current":3038.815931,"twenty":400.575047,"median":467.575731,"eighty":2963.886694,"marketCap":8746652155}],"updateTime":1780422376486},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619197455","title":"CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF001 Inhalation Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197455?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:00","pubTimestamp":1773406817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4010IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136781619","title":"Global Reformulation Breakthrough! CF PHARMTECH's Pulmonary Hypertension Drug IND Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1136781619","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136781619?lang=en_us&edition=fundamental","pubTime":"2026-03-13 13:48","pubTimestamp":1773380909,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced on March 13 that the Investigational New Drug (IND) application for its self-developed inhaled powder ICF001 has been formally accepted by China's National Medical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112141928","title":"Hong Kong Market Announcement Highlights | Mengniu Dairy Projects Annual Attributable Profit of Approximately RMB 1.4 to 1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1112141928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112141928?lang=en_us&edition=fundamental","pubTime":"2026-03-09 09:17","pubTimestamp":1773019041,"startTime":"0","endTime":"0","summary":"Significant Corporate Developments: Hengrui Pharmaceuticals (01276) announced that its adebelisib injection has received a drug clinical trial approval notice. Anjoy Foods (02648) plans to inject an...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0370786039.SGD","LU0650527681.SGD","IE0008369823.USD","LU0326950275.SGD","LU0640798160.USD","LU0737861699.HKD","BK4588","LU0651946864.USD","LU1051768304.USD","IE00B031HY20.USD","LU0287142896.SGD","LU0320764755.SGD","IE00B031J352.USD","02575","LU0823426308.USD","BK1597","LU0211977185.USD","LU1439103000.SGD","SG9999002828.SGD","LU0029875118.USD","LU0163747925.USD","IE00B29SXG58.USD","LU0672654166.SGD","LU0251143458.SGD","LU0315179316.USD","HK0000320223.HKD","HK0000306685.HKD","LU0588546209.SGD","IE0031814852.USD","IE0008368742.USD","HK0000306701.USD","IE0032834883.USD","LU0048580855.USD","02319","LU0106959298.USD","LU0543330483.HKD","LU0259732245.USD","LU1102505929.USD","LU0359201885.HKD","LU0823426480.USD","LU0128522157.USD","LU0307460666.USD","LU1769817179.HKD","LU0228367735.SGD","IE0009570106.USD","LU1115378108.SGD","02652","LU1023057109.AUD","LU0385154629.USD","LU0328353924.USD","LU0471298777.SGD","VT","IE00B0169L03.USD","BK1237","LU1224709979.USD","LU0359201612.USD","LU1102505762.USD","LU1515016050.SGD","LU0173614495.USD","LU1769817096.USD","SG9999011746.SGD","LU1048588211.SGD","BK1191","LU2045819591.USD","LU0359202008.SGD","BK1521","LU0228659784.USD","BK1553","LU0348788117.USD","BK4585","LU2125910500.SGD","LU0594300419.USD","IE00B067MR52.USD","HK0000320264.USD","BK1589","IE00B97KM107.HKD","LU0072462343.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162637253","title":"CF PHARMTECH (02652) Receives CTA Approval for Combined Nasal Spray Targeting Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1162637253","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162637253?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:02","pubTimestamp":1773014569,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) received approval from the National Medical Products Administration for a clinical trial application (CTA) concerning a nasal spray that combines olopatadine hydrochloride and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169494763","title":"CF PHARMTECH (02652) Receives NMPA Approval for Clinical Trial Application of Olopatadine Mometasone Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=1169494763","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169494763?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:50","pubTimestamp":1773013823,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that the Clinical Trial Application (CTA) for its Olopatadine Mometasone Nasal Spray has been approved by the National Medical Products Administration (NMPA) of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618569405","title":"CF Pharmtech Inc - Approval of Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2618569405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618569405?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:44","pubTimestamp":1773013496,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260308:nFWN3ZU1HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618037694","title":"CF PharmTech wins NMPA clinical trial approval for olopatadine-mometasone nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2618037694","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618037694?lang=en_us&edition=fundamental","pubTime":"2026-03-09 07:44","pubTimestamp":1773013477,"startTime":"0","endTime":"0","summary":"CF PharmTech said China’s NMPA approved its clinical trial application for an olopatadine hydrochloride and mometasone furoate monohydrate nasal spray. The product is a fixed-dose antihistamine and corticosteroid combination for moderate-to-severe allergic rhinitis in adults and children aged 12 and older. CF PharmTech said it was the first company in China to submit a generic clinical trial application for this product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260308:nNDL9yY3wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192634517","title":"CF PHARMTECH (02652) Included in Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=1192634517","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192634517?lang=en_us&edition=fundamental","pubTime":"2026-03-08 18:44","pubTimestamp":1772966656,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of securities eligible for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs. This...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","VXUS","BK4588","02652","BK1191","VT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164337640","title":"CF PHARMTECH (02652) Included in Shanghai-HK and Shenzhen-HK Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1164337640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164337640?lang=en_us&edition=fundamental","pubTime":"2026-03-08 18:42","pubTimestamp":1772966562,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that its H shares have been officially included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170564489","title":"CF PharmTech (02652) Announces Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1170564489","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170564489?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:51","pubTimestamp":1772441506,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. reported no change in its total registered share capital for February 2026, maintaining 302.22 million H shares and 109.75 million Domestic Shares at a par value of RMB 1 each,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195536964","title":"CF PharmTech (02652) Announces Share Repurchase and Updated Shareholdings","url":"https://stock-news.laohu8.com/highlight/detail?id=1195536964","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195536964?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:21","pubTimestamp":1772191310,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (02652) disclosed that on 27 February 2026, the company repurchased 30,500 of its H shares at a volume-weighted average price of HKD 38.69 per share. This transaction involved a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132176005","title":"CF PHARMTECH (02652) Repurchases 30,500 Shares for HK$1.18 Million on February 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1132176005","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132176005?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:07","pubTimestamp":1772190454,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 27, the company repurchased 30,500 of its own shares at a total cost of HK$1.18 million.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614329148","title":"CF PharmTech Files HKEX Next-Day Disclosure Return Reporting 30,500-Share Buyback at HK$38.6905 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2614329148","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614329148?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:02","pubTimestamp":1772190134,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. filed a next day disclosure return with HKEX on 27 February 2026 reporting an on-market share repurchase of 30,500 H shares to be held as treasury shares. The company paid a volume-weighted average repurchase price of HKD 38.6905 per share, with prices ranging from HKD 38.24 to HKD 38.92, for an aggregate consideration of HKD 1,180,060.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL1fBmhs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107021994","title":"CF PharmTech (02652) Announces Share Repurchase and Updates Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1107021994","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107021994?lang=en_us&edition=fundamental","pubTime":"2026-02-26 18:03","pubTimestamp":1772100193,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (02652) disclosed a share repurchase transaction dated 26 February 2026. According to the announcement, 43,000 shares were repurchased on the Hong Kong Stock Exchange at a highest...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150343712","title":"CF PharmTech (02652) Reports Share Repurchase and Updated Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1150343712","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150343712?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:00","pubTimestamp":1772017252,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (02652) disclosed a repurchase of 33,000 H shares on 25 February 2026. The highest repurchase price reached HKD 37.90, and the lowest repurchase price was HKD 36.64, for an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159834000","title":"CF PHARMTECH (02652) Allocates HK$1.2323 Million for Share Buyback on February 25","url":"https://stock-news.laohu8.com/highlight/detail?id=1159834000","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159834000?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:55","pubTimestamp":1772016902,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 25, 2026, the company repurchased 33,000 shares at a total cost of HK$1.2323 million.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614083572","title":"CF PharmTech files HKEX next-day disclosure return reporting 33,000-share repurchase at HK$37.3409 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083572","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614083572?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:51","pubTimestamp":1772016708,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc.  filed a next day disclosure return with HKEX on 25 February 2026 reporting an on-market share repurchase. The company repurchased 33,000 H shares on the Exchange at prices ranging from HKD 36.64 to HKD 37.90 per share, for an aggregate consideration of HKD 1,232,250, to be held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLbVlvdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148572483","title":"CF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1148572483","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148572483?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:30","pubTimestamp":1771990244,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million. On...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614775000","title":"CF PharmTech Wins NMPA IND Acceptance for ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=2614775000","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614775000?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:12","pubTimestamp":1771989148,"startTime":"0","endTime":"0","summary":"CF PharmTech Inc.  said China’s National Medical Products Administration  has accepted its investigational new drug  application for ICF004, an internally developed first-in-class inhaled dry powder candidate intended to treat progressive fibrosing interstitial lung disease , including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company said it will proceed with clinical start-up preparations and subsequent development activities in line with NMPA requirements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLtQ1tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614002775","title":"CF Pharmtech (HKEX: 2652.HK) Announces Nmpa Acceptance of Ind Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in Pf-Ild","url":"https://stock-news.laohu8.com/highlight/detail?id=2614002775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614002775?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:12","pubTimestamp":1771989138,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUC4CPP1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":185,"code":"91000000","status":"200"}]}}